Italia markets close in 6 hours 10 minutes

Oryzon Genomics S.A. (0RDB.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,1450+0,0154 (+0,72%)
Al 08:00AM GMT. Mercato aperto.
Schermo intero
Chiusura precedente2,1296
Aperto0,0000
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume36
Media VolumeN/D
Capitalizzazione783.725
Beta (5 anni mensile)1,17
Rapporto PE (ttm)N/D
EPS (ttm)-0,0880
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

    Collaborative study with Fox Chase Cancer Center (FCCC)Oryzon and FCCC will collaborate to assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs MADRID and SPAIN and BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the FDA has approved the Investigational New Drug (IND) a

  • GlobeNewswire

    ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference

    Final data of Phase II ALICE trial in unfit AML patients treated with iadademstat and azacitidineMADRID, Spain and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that its communication reporting final data from its ongoing and fully accrued Phase IIa ALICE trial, investigating iadademstat in combination

  • GlobeNewswire

    ORYZON to Give Updates on Corporate Progress in November

    Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022 MADRID, Spain and BOSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several intern